nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—Alzheimer's disease—Parkinson's disease	0.618	1	CtDrD
Galantamine—CHRNA4—Parkinson's disease	0.178	0.737	CbGaD
Galantamine—CYP2D6—Parkinson's disease	0.0633	0.263	CbGaD
Galantamine—CHRNB3—pons—Parkinson's disease	0.00417	0.087	CbGeAlD
Galantamine—CHRNA4—superior cervical ganglion—Parkinson's disease	0.00314	0.0655	CbGeAlD
Galantamine—CHRNA4—adrenal medulla—Parkinson's disease	0.00258	0.0537	CbGeAlD
Galantamine—CHRNG—tongue—Parkinson's disease	0.00166	0.0347	CbGeAlD
Galantamine—CHRNB3—hindbrain—Parkinson's disease	0.00162	0.0338	CbGeAlD
Galantamine—CHRNA9—embryo—Parkinson's disease	0.00153	0.0319	CbGeAlD
Galantamine—CHRNA4—autonomic nervous system—Parkinson's disease	0.00115	0.024	CbGeAlD
Galantamine—CHRNA1—tongue—Parkinson's disease	0.0011	0.023	CbGeAlD
Galantamine—CHRNA4—telencephalic ventricle—Parkinson's disease	0.00103	0.0214	CbGeAlD
Galantamine—CHRNB3—brainstem—Parkinson's disease	0.000929	0.0194	CbGeAlD
Galantamine—CHRNB3—forebrain—Parkinson's disease	0.000896	0.0187	CbGeAlD
Galantamine—CHRNA4—peripheral nervous system—Parkinson's disease	0.000831	0.0173	CbGeAlD
Galantamine—CHRNA6—brainstem—Parkinson's disease	0.000775	0.0162	CbGeAlD
Galantamine—CHRNA6—forebrain—Parkinson's disease	0.000748	0.0156	CbGeAlD
Galantamine—CHRNA4—nerve—Parkinson's disease	0.000648	0.0135	CbGeAlD
Galantamine—CHRNB3—midbrain—Parkinson's disease	0.000592	0.0123	CbGeAlD
Galantamine—CHRNA5—head—Parkinson's disease	0.000565	0.0118	CbGeAlD
Galantamine—CHRNA5—nervous system—Parkinson's disease	0.000536	0.0112	CbGeAlD
Galantamine—CHRNA5—central nervous system—Parkinson's disease	0.000516	0.0108	CbGeAlD
Galantamine—CHRNB3—head—Parkinson's disease	0.000513	0.0107	CbGeAlD
Galantamine—CHRNG—medulla oblongata—Parkinson's disease	0.000509	0.0106	CbGeAlD
Galantamine—CHRNA6—midbrain—Parkinson's disease	0.000494	0.0103	CbGeAlD
Galantamine—CHRNB3—nervous system—Parkinson's disease	0.000486	0.0101	CbGeAlD
Galantamine—CHRNA4—hindbrain—Parkinson's disease	0.000485	0.0101	CbGeAlD
Galantamine—CHRND—cardiovascular system—Parkinson's disease	0.000473	0.00986	CbGeAlD
Galantamine—CHRNB3—central nervous system—Parkinson's disease	0.000468	0.00977	CbGeAlD
Galantamine—CHRNG—midbrain—Parkinson's disease	0.000466	0.00971	CbGeAlD
Galantamine—CHRNB3—cerebellum—Parkinson's disease	0.000458	0.00955	CbGeAlD
Galantamine—CHRNB2—forebrain—Parkinson's disease	0.00043	0.00896	CbGeAlD
Galantamine—CHRNA6—head—Parkinson's disease	0.000428	0.00893	CbGeAlD
Galantamine—CHRNA3—forebrain—Parkinson's disease	0.000417	0.00869	CbGeAlD
Galantamine—CHRNA5—brain—Parkinson's disease	0.000409	0.00854	CbGeAlD
Galantamine—CHRNA6—nervous system—Parkinson's disease	0.000406	0.00847	CbGeAlD
Galantamine—CHRNG—head—Parkinson's disease	0.000404	0.00842	CbGeAlD
Galantamine—CHRNA6—central nervous system—Parkinson's disease	0.000391	0.00815	CbGeAlD
Galantamine—CHRNB4—head—Parkinson's disease	0.000389	0.00811	CbGeAlD
Galantamine—CHRNA2—forebrain—Parkinson's disease	0.000387	0.00808	CbGeAlD
Galantamine—CHRNA6—cerebellum—Parkinson's disease	0.000382	0.00797	CbGeAlD
Galantamine—CHRNB3—brain—Parkinson's disease	0.000372	0.00776	CbGeAlD
Galantamine—CHRNB4—nervous system—Parkinson's disease	0.000369	0.00769	CbGeAlD
Galantamine—CHRNB4—central nervous system—Parkinson's disease	0.000355	0.0074	CbGeAlD
Galantamine—CHRNA10—head—Parkinson's disease	0.000342	0.00714	CbGeAlD
Galantamine—CHRFAM7A—forebrain—Parkinson's disease	0.000337	0.00703	CbGeAlD
Galantamine—CHRNB2—medulla oblongata—Parkinson's disease	0.00031	0.00647	CbGeAlD
Galantamine—CHRNA6—brain—Parkinson's disease	0.00031	0.00647	CbGeAlD
Galantamine—CHRNB2—midbrain—Parkinson's disease	0.000284	0.00592	CbGeAlD
Galantamine—CHRNB4—brain—Parkinson's disease	0.000282	0.00588	CbGeAlD
Galantamine—CHRNA4—brainstem—Parkinson's disease	0.000278	0.0058	CbGeAlD
Galantamine—CHRNB2—spinal cord—Parkinson's disease	0.000277	0.00577	CbGeAlD
Galantamine—Dihydrocodeine—CYP2D6—Parkinson's disease	0.000273	0.204	CrCbGaD
Galantamine—CHRNA7—forebrain—Parkinson's disease	0.000272	0.00568	CbGeAlD
Galantamine—CHRNA4—forebrain—Parkinson's disease	0.000268	0.0056	CbGeAlD
Galantamine—CHRNA1—head—Parkinson's disease	0.000267	0.00557	CbGeAlD
Galantamine—CHRNB1—medulla oblongata—Parkinson's disease	0.00026	0.00543	CbGeAlD
Galantamine—CHRNB2—head—Parkinson's disease	0.000246	0.00513	CbGeAlD
Galantamine—CHRNA3—head—Parkinson's disease	0.000239	0.00498	CbGeAlD
Galantamine—CHRNB1—midbrain—Parkinson's disease	0.000238	0.00496	CbGeAlD
Galantamine—CHRNB2—nervous system—Parkinson's disease	0.000233	0.00486	CbGeAlD
Galantamine—CHRNB1—spinal cord—Parkinson's disease	0.000232	0.00484	CbGeAlD
Galantamine—CHRNA7—cardiovascular system—Parkinson's disease	0.00023	0.0048	CbGeAlD
Galantamine—Ethylmorphine—CYP2D6—Parkinson's disease	0.000229	0.171	CrCbGaD
Galantamine—CHRNA4—cardiovascular system—Parkinson's disease	0.000227	0.00473	CbGeAlD
Galantamine—CHRNA3—nervous system—Parkinson's disease	0.000226	0.00472	CbGeAlD
Galantamine—ACHE—medulla oblongata—Parkinson's disease	0.000226	0.00471	CbGeAlD
Galantamine—CHRNB2—central nervous system—Parkinson's disease	0.000225	0.00468	CbGeAlD
Galantamine—CHRNA2—head—Parkinson's disease	0.000222	0.00463	CbGeAlD
Galantamine—CHRNB2—cerebellum—Parkinson's disease	0.000219	0.00458	CbGeAlD
Galantamine—CHRNA3—central nervous system—Parkinson's disease	0.000218	0.00454	CbGeAlD
Galantamine—CHRNA3—cerebellum—Parkinson's disease	0.000213	0.00444	CbGeAlD
Galantamine—CHRNA2—nervous system—Parkinson's disease	0.00021	0.00439	CbGeAlD
Galantamine—Hydrocodone—CYP2D6—Parkinson's disease	0.000209	0.157	CrCbGaD
Galantamine—CHRNB1—head—Parkinson's disease	0.000206	0.0043	CbGeAlD
Galantamine—ACHE—midbrain—Parkinson's disease	0.000206	0.0043	CbGeAlD
Galantamine—CHRNA2—central nervous system—Parkinson's disease	0.000202	0.00422	CbGeAlD
Galantamine—ACHE—spinal cord—Parkinson's disease	0.000201	0.0042	CbGeAlD
Galantamine—CHRNA2—cerebellum—Parkinson's disease	0.000198	0.00413	CbGeAlD
Galantamine—CHRNA1—brain—Parkinson's disease	0.000194	0.00404	CbGeAlD
Galantamine—CHRFAM7A—head—Parkinson's disease	0.000193	0.00402	CbGeAlD
Galantamine—Oxycodone—CYP2D6—Parkinson's disease	0.000191	0.143	CrCbGaD
Galantamine—CHRNB1—cerebellum—Parkinson's disease	0.000184	0.00384	CbGeAlD
Galantamine—CYP2D6—hindbrain—Parkinson's disease	0.000184	0.00384	CbGeAlD
Galantamine—CHRFAM7A—nervous system—Parkinson's disease	0.000183	0.00382	CbGeAlD
Galantamine—Codeine—CYP2D6—Parkinson's disease	0.000182	0.136	CrCbGaD
Galantamine—CHRNB2—brain—Parkinson's disease	0.000178	0.00372	CbGeAlD
Galantamine—CHRNA4—midbrain—Parkinson's disease	0.000177	0.0037	CbGeAlD
Galantamine—CHRFAM7A—central nervous system—Parkinson's disease	0.000176	0.00367	CbGeAlD
Galantamine—CHRNA4—spinal cord—Parkinson's disease	0.000173	0.00361	CbGeAlD
Galantamine—CHRNA3—brain—Parkinson's disease	0.000173	0.00361	CbGeAlD
Galantamine—CHRNA2—brain—Parkinson's disease	0.000161	0.00335	CbGeAlD
Galantamine—ACHE—cerebellum—Parkinson's disease	0.00016	0.00333	CbGeAlD
Galantamine—BCHE—brainstem—Parkinson's disease	0.000159	0.00332	CbGeAlD
Galantamine—CHRNA7—head—Parkinson's disease	0.000156	0.00325	CbGeAlD
Galantamine—CHRNA4—head—Parkinson's disease	0.000154	0.00321	CbGeAlD
Galantamine—BCHE—forebrain—Parkinson's disease	0.000154	0.0032	CbGeAlD
Galantamine—CHRNB1—brain—Parkinson's disease	0.00015	0.00312	CbGeAlD
Galantamine—CHRNA7—nervous system—Parkinson's disease	0.000148	0.00308	CbGeAlD
Galantamine—Morphine—CYP2D6—Parkinson's disease	0.000148	0.11	CrCbGaD
Galantamine—CHRNA4—nervous system—Parkinson's disease	0.000146	0.00304	CbGeAlD
Galantamine—CHRNA7—central nervous system—Parkinson's disease	0.000142	0.00297	CbGeAlD
Galantamine—CHRNA4—central nervous system—Parkinson's disease	0.00014	0.00293	CbGeAlD
Galantamine—CHRFAM7A—brain—Parkinson's disease	0.00014	0.00292	CbGeAlD
Galantamine—CHRNA4—cerebellum—Parkinson's disease	0.000137	0.00286	CbGeAlD
Galantamine—BCHE—cardiovascular system—Parkinson's disease	0.00013	0.00271	CbGeAlD
Galantamine—ACHE—brain—Parkinson's disease	0.00013	0.0027	CbGeAlD
Galantamine—CHRNA7—brain—Parkinson's disease	0.000113	0.00236	CbGeAlD
Galantamine—CHRNA4—brain—Parkinson's disease	0.000111	0.00232	CbGeAlD
Galantamine—BCHE—medulla oblongata—Parkinson's disease	0.000111	0.00231	CbGeAlD
Galantamine—CYP2D6—brainstem—Parkinson's disease	0.000105	0.0022	CbGeAlD
Galantamine—Morphine—ABCB1—Parkinson's disease	0.000105	0.0788	CrCbGaD
Galantamine—CYP2D6—forebrain—Parkinson's disease	0.000102	0.00212	CbGeAlD
Galantamine—BCHE—midbrain—Parkinson's disease	0.000101	0.00212	CbGeAlD
Galantamine—BCHE—spinal cord—Parkinson's disease	9.89e-05	0.00206	CbGeAlD
Galantamine—BCHE—head—Parkinson's disease	8.79e-05	0.00183	CbGeAlD
Galantamine—BCHE—nervous system—Parkinson's disease	8.34e-05	0.00174	CbGeAlD
Galantamine—BCHE—central nervous system—Parkinson's disease	8.03e-05	0.00167	CbGeAlD
Galantamine—BCHE—cerebellum—Parkinson's disease	7.85e-05	0.00164	CbGeAlD
Galantamine—BCHE—brain—Parkinson's disease	6.37e-05	0.00133	CbGeAlD
Galantamine—CYP2D6—head—Parkinson's disease	5.83e-05	0.00122	CbGeAlD
Galantamine—CYP3A4—nervous system—Parkinson's disease	5.61e-05	0.00117	CbGeAlD
Galantamine—CYP2D6—nervous system—Parkinson's disease	5.52e-05	0.00115	CbGeAlD
Galantamine—CYP3A4—central nervous system—Parkinson's disease	5.4e-05	0.00113	CbGeAlD
Galantamine—CYP2D6—central nervous system—Parkinson's disease	5.32e-05	0.00111	CbGeAlD
Galantamine—CYP2D6—cerebellum—Parkinson's disease	5.2e-05	0.00108	CbGeAlD
Galantamine—CYP2D6—brain—Parkinson's disease	4.22e-05	0.000881	CbGeAlD
Galantamine—CHRNA4—Neuronal System—DLG4—Parkinson's disease	2.17e-05	0.000236	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—MAOA—Parkinson's disease	2.16e-05	0.000235	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—COMT—Parkinson's disease	2.15e-05	0.000234	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—HSPA8—Parkinson's disease	2.15e-05	0.000234	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	2.14e-05	0.000233	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—MAOA—Parkinson's disease	2.14e-05	0.000233	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—GRIN2B—Parkinson's disease	2.12e-05	0.00023	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	2.11e-05	0.00023	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—INS—Parkinson's disease	2.11e-05	0.000229	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—CHRNA4—Parkinson's disease	2.09e-05	0.000228	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—GRIK2—Parkinson's disease	2.09e-05	0.000228	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—SLC6A3—Parkinson's disease	2.09e-05	0.000227	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—GBA—Parkinson's disease	2.06e-05	0.000224	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—COMT—Parkinson's disease	2.05e-05	0.000223	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—MAOA—Parkinson's disease	2.03e-05	0.000221	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—SLC18A2—Parkinson's disease	2.03e-05	0.00022	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—DLG4—Parkinson's disease	2.02e-05	0.000219	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—HSPA9—Parkinson's disease	1.99e-05	0.000217	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—GRIN2B—Parkinson's disease	1.97e-05	0.000215	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—SLC6A3—Parkinson's disease	1.94e-05	0.000211	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—MAPK8—Parkinson's disease	1.93e-05	0.00021	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—HSPA8—Parkinson's disease	1.92e-05	0.000209	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	1.92e-05	0.000208	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	1.91e-05	0.000208	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—INS—Parkinson's disease	1.88e-05	0.000204	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—GBA—Parkinson's disease	1.84e-05	0.0002	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—MAPK8—Parkinson's disease	1.82e-05	0.000198	CbGpPWpGaD
Galantamine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—Parkinson's disease	1.81e-05	0.000197	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—DLG4—Parkinson's disease	1.8e-05	0.000196	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—CHRNA4—Parkinson's disease	1.8e-05	0.000196	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—HSPA9—Parkinson's disease	1.78e-05	0.000194	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—COMT—Parkinson's disease	1.77e-05	0.000193	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—TNF—Parkinson's disease	1.77e-05	0.000192	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—MAOA—Parkinson's disease	1.76e-05	0.000192	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—GRIN2B—Parkinson's disease	1.76e-05	0.000191	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	1.74e-05	0.000189	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—SLC6A3—Parkinson's disease	1.73e-05	0.000189	CbGpPWpGaD
Galantamine—CYP3A4—Tryptophan metabolism—CYP2E1—Parkinson's disease	1.73e-05	0.000189	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—Parkinson's disease	1.72e-05	0.000187	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—MAOB—Parkinson's disease	1.67e-05	0.000182	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ABL1—Parkinson's disease	1.67e-05	0.000181	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	1.66e-05	0.000181	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	1.66e-05	0.00018	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—COMT—Parkinson's disease	1.65e-05	0.00018	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—HSPA8—Parkinson's disease	1.65e-05	0.000179	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—Parkinson's disease	1.64e-05	0.000179	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—MAOA—Parkinson's disease	1.64e-05	0.000179	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ABCB1—Parkinson's disease	1.62e-05	0.000176	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—CHRNA4—Parkinson's disease	1.6e-05	0.000174	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—DLG4—Parkinson's disease	1.55e-05	0.000168	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—Parkinson's disease	1.53e-05	0.000167	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTA4—Parkinson's disease	1.52e-05	0.000166	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—Parkinson's disease	1.51e-05	0.000164	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—GRIN2B—Parkinson's disease	1.51e-05	0.000164	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTA4—Parkinson's disease	1.5e-05	0.000163	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—SLC6A3—Parkinson's disease	1.49e-05	0.000162	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—COMT—Parkinson's disease	1.47e-05	0.00016	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—HSPA8—Parkinson's disease	1.47e-05	0.00016	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—MAOA—Parkinson's disease	1.46e-05	0.000159	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—FASLG—Parkinson's disease	1.46e-05	0.000159	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	1.43e-05	0.000156	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL6—Parkinson's disease	1.42e-05	0.000155	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—RPL6—Parkinson's disease	1.42e-05	0.000155	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	1.4e-05	0.000152	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—TNF—Parkinson's disease	1.39e-05	0.000151	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	1.38e-05	0.00015	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—DLG4—Parkinson's disease	1.38e-05	0.00015	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—MAOB—Parkinson's disease	1.36e-05	0.000148	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	1.36e-05	0.000147	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	1.35e-05	0.000147	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—GRIN2B—Parkinson's disease	1.35e-05	0.000147	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—ATP6AP2—Parkinson's disease	1.35e-05	0.000147	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—SLC6A3—Parkinson's disease	1.33e-05	0.000145	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PLA2G6—Parkinson's disease	1.28e-05	0.00014	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—RPL6—Parkinson's disease	1.27e-05	0.000138	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—COMT—Parkinson's disease	1.27e-05	0.000138	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—MAOA—Parkinson's disease	1.26e-05	0.000137	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—Parkinson's disease	1.24e-05	0.000135	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—IL6—Parkinson's disease	1.23e-05	0.000134	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—DCTN1—Parkinson's disease	1.23e-05	0.000134	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MCCC1—Parkinson's disease	1.21e-05	0.000132	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ND3—Parkinson's disease	1.21e-05	0.000132	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—TNF—Parkinson's disease	1.21e-05	0.000131	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—ATP6AP2—Parkinson's disease	1.2e-05	0.000131	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—IL6—Parkinson's disease	1.16e-05	0.000127	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PLA2G6—Parkinson's disease	1.15e-05	0.000125	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TALDO1—Parkinson's disease	1.14e-05	0.000124	CbGpPWpGaD
Galantamine—ACHE—Metabolism—OMD—Parkinson's disease	1.14e-05	0.000124	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	1.14e-05	0.000124	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—COMT—Parkinson's disease	1.13e-05	0.000123	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL6—Parkinson's disease	1.12e-05	0.000122	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—MAOA—Parkinson's disease	1.12e-05	0.000122	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—DCTN1—Parkinson's disease	1.1e-05	0.00012	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ND3—Parkinson's disease	1.08e-05	0.000117	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MCCC1—Parkinson's disease	1.08e-05	0.000117	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NDUFB11—Parkinson's disease	1.08e-05	0.000117	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—RPL23A—Parkinson's disease	1.08e-05	0.000117	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—RPL14—Parkinson's disease	1.08e-05	0.000117	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GCH1—Parkinson's disease	1.03e-05	0.000112	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TALDO1—Parkinson's disease	1.01e-05	0.00011	CbGpPWpGaD
Galantamine—BCHE—Metabolism—OMD—Parkinson's disease	1.01e-05	0.00011	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—RPS8—Parkinson's disease	1e-05	0.000109	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTA4—Parkinson's disease	9.96e-06	0.000108	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—TNF—Parkinson's disease	9.84e-06	0.000107	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTA4—Parkinson's disease	9.82e-06	0.000107	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL6—Parkinson's disease	9.74e-06	0.000106	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NDUFB11—Parkinson's disease	9.61e-06	0.000105	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—RPL23A—Parkinson's disease	9.61e-06	0.000105	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—RPL14—Parkinson's disease	9.61e-06	0.000105	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	9.35e-06	0.000102	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	9.27e-06	0.000101	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP2E1—Parkinson's disease	9.23e-06	0.0001	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GCH1—Parkinson's disease	9.17e-06	9.98e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—FBP1—Parkinson's disease	9.16e-06	9.97e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GBA—Parkinson's disease	9.16e-06	9.97e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—DBH—Parkinson's disease	9.16e-06	9.97e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP2E1—Parkinson's disease	9.1e-06	9.9e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—RPS8—Parkinson's disease	8.96e-06	9.75e-05	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—MAOB—Parkinson's disease	8.88e-06	9.66e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	8.27e-06	9e-05	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	8.21e-06	8.93e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—DBH—Parkinson's disease	8.17e-06	8.89e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—FBP1—Parkinson's disease	8.17e-06	8.89e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GBA—Parkinson's disease	8.17e-06	8.89e-05	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL6—Parkinson's disease	7.94e-06	8.64e-05	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—COMT—Parkinson's disease	7.65e-06	8.32e-05	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTP1—Parkinson's disease	7.61e-06	8.28e-05	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—MAOA—Parkinson's disease	7.59e-06	8.26e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—COMT—Parkinson's disease	7.54e-06	8.21e-05	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	7.54e-06	8.2e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTP1—Parkinson's disease	7.51e-06	8.17e-05	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTM1—Parkinson's disease	6.99e-06	7.61e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTM1—Parkinson's disease	6.9e-06	7.5e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—DDC—Parkinson's disease	6.72e-06	7.32e-05	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP2D6—Parkinson's disease	6.6e-06	7.18e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP2D6—Parkinson's disease	6.51e-06	7.08e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTA4—Parkinson's disease	6.35e-06	6.91e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	6.27e-06	6.82e-05	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP2E1—Parkinson's disease	6.03e-06	6.56e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—DDC—Parkinson's disease	6e-06	6.53e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—IGF2—Parkinson's disease	5.99e-06	6.52e-05	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	5.97e-06	6.49e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP2E1—Parkinson's disease	5.95e-06	6.47e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PLA2G6—Parkinson's disease	5.72e-06	6.22e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTA4—Parkinson's disease	5.67e-06	6.16e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MAOB—Parkinson's disease	5.66e-06	6.16e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	5.59e-06	6.09e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	5.39e-06	5.86e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGF2—Parkinson's disease	5.34e-06	5.81e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PLA2G6—Parkinson's disease	5.1e-06	5.55e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MAOB—Parkinson's disease	5.05e-06	5.49e-05	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—COMT—Parkinson's disease	5e-06	5.44e-05	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	4.98e-06	5.41e-05	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	4.96e-06	5.4e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ND3—Parkinson's disease	4.96e-06	5.39e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MCCC1—Parkinson's disease	4.96e-06	5.39e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	4.93e-06	5.36e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	4.91e-06	5.34e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	4.81e-06	5.23e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—OMD—Parkinson's disease	4.66e-06	5.07e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TALDO1—Parkinson's disease	4.66e-06	5.07e-05	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	4.57e-06	4.97e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	4.51e-06	4.91e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	4.42e-06	4.81e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GCH1—Parkinson's disease	4.22e-06	4.59e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP2D6—Parkinson's disease	4.21e-06	4.58e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CTGF—Parkinson's disease	4.13e-06	4.49e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—INS—Parkinson's disease	3.98e-06	4.33e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP2E1—Parkinson's disease	3.85e-06	4.19e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NQO1—Parkinson's disease	3.8e-06	4.14e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GBA—Parkinson's disease	3.76e-06	4.09e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—FBP1—Parkinson's disease	3.76e-06	4.09e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—DBH—Parkinson's disease	3.76e-06	4.09e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP2D6—Parkinson's disease	3.75e-06	4.08e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TH—Parkinson's disease	3.75e-06	4.08e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CTGF—Parkinson's disease	3.68e-06	4.01e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYCS—Parkinson's disease	3.6e-06	3.92e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—INS—Parkinson's disease	3.55e-06	3.86e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP2E1—Parkinson's disease	3.43e-06	3.73e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NQO1—Parkinson's disease	3.39e-06	3.69e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TH—Parkinson's disease	3.35e-06	3.64e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ND3—Parkinson's disease	3.24e-06	3.53e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MCCC1—Parkinson's disease	3.24e-06	3.53e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYCS—Parkinson's disease	3.21e-06	3.49e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—COMT—Parkinson's disease	3.19e-06	3.47e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTP1—Parkinson's disease	3.17e-06	3.45e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MAOA—Parkinson's disease	3.17e-06	3.44e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—HMOX1—Parkinson's disease	3.13e-06	3.4e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—OMD—Parkinson's disease	3.05e-06	3.32e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TALDO1—Parkinson's disease	3.05e-06	3.32e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ABCB1—Parkinson's disease	3e-06	3.27e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTM1—Parkinson's disease	2.92e-06	3.17e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	2.89e-06	3.14e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—COMT—Parkinson's disease	2.84e-06	3.09e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTP1—Parkinson's disease	2.83e-06	3.08e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MAOA—Parkinson's disease	2.82e-06	3.07e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GPX1—Parkinson's disease	2.79e-06	3.04e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—HMOX1—Parkinson's disease	2.79e-06	3.04e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—DDC—Parkinson's disease	2.76e-06	3e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GCH1—Parkinson's disease	2.76e-06	3e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ABCB1—Parkinson's disease	2.68e-06	2.92e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	2.6e-06	2.83e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTM1—Parkinson's disease	2.6e-06	2.83e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MTHFR—Parkinson's disease	2.58e-06	2.8e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GPX1—Parkinson's disease	2.49e-06	2.71e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GBA—Parkinson's disease	2.46e-06	2.67e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—DBH—Parkinson's disease	2.46e-06	2.67e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.46e-06	2.67e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—APOE—Parkinson's disease	2.4e-06	2.61e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	2.35e-06	2.55e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MAOB—Parkinson's disease	2.32e-06	2.53e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MTHFR—Parkinson's disease	2.3e-06	2.5e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—APOE—Parkinson's disease	2.14e-06	2.33e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—INS—Parkinson's disease	2.05e-06	2.23e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—INS—Parkinson's disease	1.83e-06	1.99e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—DDC—Parkinson's disease	1.8e-06	1.96e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.7e-06	1.85e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CTGF—Parkinson's disease	1.69e-06	1.84e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	1.58e-06	1.72e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NQO1—Parkinson's disease	1.56e-06	1.7e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TH—Parkinson's disease	1.54e-06	1.67e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.53e-06	1.67e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.52e-06	1.65e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYCS—Parkinson's disease	1.48e-06	1.61e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—COMT—Parkinson's disease	1.31e-06	1.42e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	1.3e-06	1.42e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MAOA—Parkinson's disease	1.3e-06	1.41e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	1.28e-06	1.4e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1.23e-06	1.34e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	1.2e-06	1.3e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GPX1—Parkinson's disease	1.15e-06	1.25e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.13e-06	1.23e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.11e-06	1.2e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	1.06e-06	1.15e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.03e-06	1.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.02e-06	1.11e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TH—Parkinson's disease	1.01e-06	1.09e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—APOE—Parkinson's disease	9.84e-07	1.07e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYCS—Parkinson's disease	9.65e-07	1.05e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—COMT—Parkinson's disease	8.55e-07	9.3e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTP1—Parkinson's disease	8.51e-07	9.26e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MAOA—Parkinson's disease	8.49e-07	9.24e-06	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—INS—Parkinson's disease	8.41e-07	9.15e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HMOX1—Parkinson's disease	8.39e-07	9.13e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ABCB1—Parkinson's disease	8.06e-07	8.76e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTM1—Parkinson's disease	7.82e-07	8.51e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GPX1—Parkinson's disease	7.49e-07	8.15e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MTHFR—Parkinson's disease	6.91e-07	7.52e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—APOE—Parkinson's disease	6.43e-07	7e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—INS—Parkinson's disease	5.5e-07	5.98e-06	CbGpPWpGaD
